Ultrasensitive Impedimetric Biosensor for Ovarian Cancer Screening

被引:0
|
作者
Gundagatti, Shilpa [1 ]
Srivastava, Sudha [1 ]
机构
[1] Jaypee Inst Informat Technol, Dept Biotechnol, Noida, India
关键词
Biosensors design; Ovarian cancer detection; miRNA-21; Magnetite selenium nanocomposites; Gold nanoparticles; ELECTROCHEMICAL SENSING PLATFORM; LABEL; MICRORNAS; GRAPHENE;
D O I
10.1007/s12088-024-01307-5
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Ovarian cancer is a significant health concern among the female vulnerable populations due to delayed diagnosis. Point-of-care devices that can be utilized for mass screening of the population may improve patient survival through early diagnosis. In this context, we report an ultrasensitive DNA-based nano-biosensor for the quantification of cancer biomarker miRNA-21 using a label-free sensing technique. Magnetite selenium (Fe3O4-Se\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\textrm{Fe}_3\textrm{O}_4{-}\textrm{Se}$$\end{document}) nanocomposite was prepared by co-precipitation method followed by characterization using TEM, EDX, FTIR, VSM, and XRD. The average size of the nanomaterial was found to be 20 nm with a low polydispersity index of 0.2. The biosensor was fabricated by immobilizing a single-stranded DNA probe specific to miRNA-21 onto the Fe3O4-Se\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\textrm{Fe}_3\textrm{O}_4{-}\textrm{Se}$$\end{document} nanocomposite modified electrode surface. At the working electrode/electrolyte interface, the binding of the DNA probe results in decreased charge transfer impedance. The developed magnetite-based impedimetric biosensor demonstrated a linear variation of resistance to charge transfer with miRNA-21 concentration (75 zM to 0.751 pM). The ultrasensitive low limits of detection (75 zM), the sensitivity of 1774.34 Omega\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\varOmega $$\end{document}/mu\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\upmu $$\end{document}g/mu\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\upmu $$\end{document}L/cm2\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\textrm{cm}<^>2$$\end{document} and high selectivity over other biomarkers (miRNAs-miRNA-30e, miRNA-143, miRNA-204, DNA, protein, and cocktail of all makes it suitable for early diagnosis. Furthermore, owing to miRNA-21 prognostic as well as diagnostic value, the magnetite-based miRNA-21 impedimetric biosensor offers the promise of a sensitive consumer-centric device for mass screening of ovarian cancer.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Ovarian cancer screening
    Eason, EL
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (04) : 447 - 447
  • [32] Ovarian cancer screening
    DePriest, P
    vanNagell, JR
    CURRENT PROBLEMS IN OBSTETRICS GYNECOLOGY AND FERTILITY, 1996, 19 (03) : 99 - 109
  • [33] Ovarian cancer screening
    Neesham, Deborah
    AUSTRALIAN FAMILY PHYSICIAN, 2007, 36 (03) : 126 - 128
  • [34] Screening for ovarian cancer
    Kehoe, Sean
    MATURITAS, 2015, 81 (04) : 423 - 424
  • [35] Screening for Ovarian Cancer
    Buckler, Aileen
    Luu, Phuong
    AMERICAN FAMILY PHYSICIAN, 2013, 87 (10) : 709 - 710
  • [36] Ovarian cancer screening
    Menon, U
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (04) : 323 - 324
  • [37] Ovarian cancer screening
    Urban, N
    McIntosh, MW
    Andersen, M
    Karlan, BY
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2003, 17 (04) : 989 - +
  • [38] Ovarian cancer screening
    Menon, Usha
    CLINICAL CANCER RESEARCH, 2016, 22
  • [39] Ovarian cancer screening
    Kyrgiou, M.
    Tsoumpou, I.
    Martin-Hirsch, P.
    Arbyn, M.
    Prendiville, W.
    Koliopoulos, G.
    Dalkalitsis, N.
    Stamatopoulos, P.
    Paraskevaidis, E.
    ANTICANCER RESEARCH, 2006, 26 (6C) : 4793 - 4801
  • [40] Screening for ovarian cancer
    Anderiesz, C
    Quinn, MA
    MEDICAL JOURNAL OF AUSTRALIA, 2003, 178 (12) : 655 - 656